论文部分内容阅读
食管癌是我国高发的恶性肿瘤之一,发病率居全国各类恶性肿瘤第5位,死亡率居第4位[1]。由于早期食管癌症状不明显,就诊患者60%已达中晚期,失去手术机会。以化疗、放疗为主的联合治疗能有效控制食管癌局部肿瘤的发展,减少远处转移,从而提高患者生存率。食管癌联合化疗优于单药化疗,随着抗肿瘤新药的开发,紫杉醇(Paclitaxel,PTX)是目前治疗食管癌最有效药物之一,单药有效率32%,联合化疗中多与顺铂(DDP)、氟尿嘧啶(5-Fu)联用,有效率67%~77%[2]。老年食管癌患者因年纪大、合并有基础疾病,往往难以耐受手术创伤,因
Esophageal cancer is one of the high incidence of malignant tumors in our country, the incidence rate ranks the fifth in all kinds of malignant tumors in the country, with the fourth highest mortality rate [1]. As early symptoms of esophageal cancer is not obvious, 60% of patients have reached the mid-late treatment, loss of chance of surgery. Chemotherapy, radiotherapy-based combination therapy can effectively control the development of esophageal cancer, reduce distant metastasis, thereby enhancing patient survival. Combination of esophageal cancer chemotherapy is better than single-drug chemotherapy, with the development of new antitumor drugs, paclitaxel (Paclitaxel, PTX) is currently one of the most effective drugs for the treatment of esophageal cancer, single drug effective rate of 32%, combined with chemotherapy more with cisplatin DDP), fluorouracil (5-Fu) combination, the effective rate of 67% to 77% [2]. Elderly patients with esophageal cancer due to age, with underlying diseases, often difficult to tolerate surgical trauma, because